Corbus Pharmaceuticals Holdings, Inc. (CRBP) Announces Resolution of Inflammation, Infection and Tissue Regeneration Conference

0
987

Corbus Pharmaceuticals Announces Resolution of Inflammation, Infection and Tissue Regeneration Conference

Corbus Pharmaceuticals Holdings, Inc. (CRBP) (“Corbus” or the “Company”), a Phase 3 clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare, chronic and serious inflammatory diseases, announced that it will be presenting at the Resolution of Inflammation, Infection and Tissue Regeneration Conference in partnership with the New York Academy of Sciences (NYAS), taking place on Tuesday, June 26, 2018 in New York City.

Dr. Mark Tepper, Corbus’ President and Chief Scientific Officer, will present on Tuesday, June 26th in a talk titled, “Resolution of Inflammatory/Fibrotic Diseases by Lenabasum through activation of the Endocannabinoid Specialized Pro-Resolution Mediator Pathway,” and will sit on a panel titled, “Barriers to Translation in Inflammatory Disease.”

The conference will convene 18 preeminent researchers who will discuss mechanisms of inflammation, tissue repair and regeneration, and explore existing challenges to clinical approaches. Keynote speakers include:

  • Charles N. Serhan, PhD, DSc, Brigham and Women’s Hospital, Harvard Medical School and a member of the Scientific Advisory Board of Corbus
  • Catherine Godson, PhD, University College Dublin
  • Kevin J. Tracey, MD, The Feinstein Institute for Medical Research

“Advancements in scientific research and drug discovery is rapidly shaping our understanding of the important role that resolution plays in inflammation, infection and tissue regeneration, otherwise known as Resolution Pharmacology,” said Dr. Tepper. “We are proud to collaborate in facilitating this important symposium, and we look forward to productive discussions to further advance the field.”

 To register for the conference or to view the live webcast click on the link here.

Note to journalists: Press passes for this program are available upon request. Please email: [email protected] or [email protected]

About New York Academy of Sciences

The New York Academy of Sciences (NYAS) is an independent, not-for-profit organization that since 1817 has been committed to advancing science, technology, and society worldwide. With more than 20,000 members around the world, the Academy is creating a global community of science for the benefit of humanity. The Academy’s core mission is to advance scientific knowledge, positively impact the major global challenges of society with science-based solutions and increase the number of scientifically informed individuals in society at large. Please visit us online at www.nyas.org.

About Corbus

Corbus Pharmaceuticals Holdings, Inc. is a Phase 3 clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. The Company’s lead product candidate, lenabasum, is a novel, synthetic oral endocannabinoid-mimetic drug designed to resolve chronic inflammation and fibrotic processes. Lenabasum is currently being evaluated in systemic sclerosis, cystic fibrosis, dermatomyositis, and systemic lupus erythematosus.

For more information, please visit www.CorbusPharma.com and connect with the Company on Twitter, LinkedIn, Google+ and Facebook.

Forward-Looking Statements

This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company’s product development, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statement that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management’s current beliefs and assumptions.

These statements may be identified by the use of forward-looking expressions, including, but not limited to, “expect,” “anticipate,” “intend,” “plan,” “believe,” “estimate,” “potential, “predict,” “project,” “should,” “would” and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company’s filings with the Securities and Exchange Commission. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

LEAVE A REPLY

Please enter your comment!
Please enter your name here